Diagnosing Dx

Elevra Consulting
  • 5.0 (1)
  • Life Sciences
  • Updated Weekly

How do we transform cutting-edge scientific discoveries into life-saving diagnostics? On Diagnosing Dx, we explore the scientific innovation driving diagnostics forward, unpack industry challenges, and spotlight success stories. Join us as we speak with leading researchers and innovators at the forefront of Dx. Learn to: 🔹 Navigate industry challenges 🔹 Understand emerging science 🔹 Strategise for growth 🔹 Gain future-focused insight Essential listening for everyone involved in bringing new sciences to life in the Dx and Omics industry, Subscribe now!

  1. 2d ago

    98% of Cancer Patients Outside the US Miss Genomic Testing. Can AI Change That?

    In this episode of Diagnosing Dx, David Filby is joined by Travis Wold, Chief Executive Officer at Imagenomix. Travis brings experience across cancer diagnostics, genomics, liquid biopsy, and international commercialization. We explore how Imagenomix is using AI to help make genomic testing more accessible to cancer patients globally. With around 98% of cancer patients outside the US not receiving NGS testing, Travis explains how analysing standard H&E pathology images could help identify patients who are more likely to benefit from confirmatory genomic testing. We also discuss Imagenomix’s commercial strategy, digital pathology partnerships, and the longer-term potential for AI to support more precise treatment decisions in oncology. Key takeaways: 🔹 Why access to genomic testing remains extremely limited outside the US 🔹 How Imagenomix uses AI to identify mutation signals from standard H&E pathology images 🔹 Why AI screening could reduce the cost and volume of unnecessary NGS testing 🔹 How digital pathology partnerships could help Imagenomix scale globally 🔹 Why predicting treatment response could become the next major step for AI in precision oncology Chapters: 00:59 Introduction and Travis Wold’s background 05:29 From cancer diagnostics to the global genomic testing problem 09:42 The limitations of NGS and where AI fits into the workflow 13:36 Imagenomix’s mission and the 98% genomic testing gap 17:42 Funding, digital pathology partnerships, and commercial traction 20:36 Regulatory strategy, screening, and the path towards companion diagnostics 23:13 Can AI predict which cancer patients will respond to treatment? 32:56 Scaling Imagenomix globally and the milestones ahead Guest: Travis Wold Chief Executive Officer at Imagenomix LinkedIn: https://www.linkedin.com/in/travisjwold/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    98% of Cancer Patients Outside the US Miss Genomic Testing. Can AI Change That?

  2. Aug 11

    Could 20-Minute Hormone Testing Transform Patient Care? Nedal Safwat, SVP at Canatu

    In this episode of Diagnosing Dx, David Filby is joined by Nedal Safwat, Senior Vice President of Medical Diagnostics at Canatu and President of Canatu Inc. With more than 20 years in diagnostics, Nedal has held leadership roles across Cepheid, QIAGEN, bioMérieux and Luminex. He now leads Canatu’s expansion into medical diagnostics, taking the company’s carbon nanotube technology into point-of-care testing. Nedal explains why Canatu has chosen hormone testing and sepsis as its first areas of focus, and why the company started with the unmet clinical need rather than trying to find an application for its technology. We also discuss the opportunity for faster hormone testing, the shift towards decentralised diagnostics, reimbursement and design-to-cost, and how Canatu is combining the speed of a startup with the infrastructure and backing of an established company. Key takeaways: 🔹 Why Canatu is bringing carbon nanotube technology into medical diagnostics 🔹 Why hormone testing and sepsis were selected as the company’s first focus areas 🔹 Why diagnostics companies should start with the unmet need and work backwards 🔹 How point-of-care hormone testing could improve convenience and reduce patient drop-off 🔹 Why reimbursement, cost and customer validation need to be considered from the beginning Chapters: 00:53 Introduction and Nedal Safwat’s background 07:18 Canatu and the move into medical diagnostics 13:02 Why hormone testing and sepsis? 17:26 Starting with the unmet need and product-market fit 21:29 Partnerships, personalised hormone testing and patient demand 27:52 Product development and the path to commercialisation 32:57 Reimbursement, design-to-cost and startup culture 40:30 Future milestones and the diagnostics market outlook Guest: Nedal Safwat Senior Vice President, Medical Diagnostics at Canatu President, Canatu Inc. LinkedIn: https://www.linkedin.com/in/nedal-safwat/ Learn more about Canatu, Medical Diagnostics here: https://canatu.com/products/medical-diagnostics/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Could 20-Minute Hormone Testing Transform Patient Care? Nedal Safwat, SVP at Canatu

  3. Aug 4

    Could a $127M Seed Round Change Women's Health Forever? - Dean Remy, Co-Founder @ Mativa Dx

    In this episode of Diagnosing Dx, David Filby is joined by Dean Remy, Co-Founder and Chief Commercial Officer at Mativa Diagnostics. Dean brings 35 years of experience across diagnostics, biotechnology, and therapeutics. He explains why pregnancy testing has barely changed in 50 years and how the traditional positive-or-negative result can leave women without critical information during the earliest weeks of pregnancy. Mativa is developing a reusable handheld device combining multiplex biomarker testing, graphene nanosensor technology, an AI-enabled app, and immediate care navigation. The company is also building a large longitudinal maternal biorepository to support future diagnostics, biomarker discovery, and therapeutic development. This is a practical conversation about maternal health innovation, consumer access, partnerships, regulation, data, and building a platform designed to support women throughout the pregnancy journey. Key takeaways: 🔹 Why the traditional pregnancy test does not provide women with enough early information 🔹 How Mativa plans to identify risks such as ectopic pregnancy and pre-eclampsia 🔹 Why a longitudinal maternal biorepository could transform diagnostics and therapeutic development 🔹 How retail, healthcare, pharmaceutical, and diagnostic partnerships could accelerate adoption 🔹 Why supporting the complete patient journey could define the next generation of diagnostics Chapters: 01:08 Introduction and Dean Remy’s background 03:24 Why maternal health urgently needs innovation 06:28 Mativa’s approach and the technology behind the platform 11:42 Building a comprehensive maternal biorepository 14:24 Commercial strategy and market positioning 17:13 Regulatory and reimbursement pathways 20:18 Capital raising and strategic partnerships 25:34 The future of Mativa and maternal diagnostics Guest: Dean Remy Co-Founder and Chief Commercial Officer at Mativa Diagnostics LinkedIn: https://www.linkedin.com/in/scisourceremy/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Could a $127M Seed Round Change Women's Health Forever? - Dean Remy, Co-Founder @ Mativa Dx

  4. Jul 28

    Red Drop’s Bet on Pain-Free Blood Collection and the Next Wave of Diagnostics

    In this episode of Diagnosing Dx, David Filby is joined by Thomas Briggs, Chief Growth Officer at RedDrop Dx. Thomas brings more than 25 years of diagnostics and healthcare growth experience, spanning pharma, big diagnostics, medtech, and startup environments. In this conversation, we explore one of the most overlooked parts of diagnostics: blood collection, and why the process still looks far too similar to what it did decades ago. Thomas breaks down where arm-based micro-sampling could genuinely change patient experience, from paediatrics and neurodivergent patients to home testing, clinical trials, and difficult vein access. We also get into the commercial reality behind a product like this: where the most promising markets are, why education still matters, how labs and platforms need to adapt, and what it takes to build a medtech business without following the usual VC-heavy playbook. This is a practical conversation about workflow, access, patient experience, and what happens when a simple shift in blood collection could unlock broader changes across diagnostics and healthcare delivery. Key takeaways: 🔹 Why blood collection remains one of the least-innovated parts of diagnostics 🔹 Where arm-based micro-sampling could have the biggest clinical and commercial impact 🔹 Why paediatrics, neurodivergent patients, and difficult vein access are such important use cases 🔹 How home sampling could change clinical trials, routine monitoring, and direct-to-consumer care 🔹 What it takes to commercialise a medtech product in both consumer and managed-care settings Chapters: 01:51 Thomas Briggs’ background in diagnostics, pharma, and medtech 06:28 Moving from big corporates into startups 11:04 What RedDrop Dx is building and how the device works 14:39 Where the biggest commercial opportunities are for arm-based micro-sampling 18:48 Why education and awareness are still a major challenge 21:22 RedDrop Dx’s story so far and why it was bootstrapped 26:05 How the company is building for growth across different market segments 30:10 Future milestones, home collection clearance, and expansion into Europe 31:31 Thomas’s outlook on diagnostics, home testing, and micro-sampling in 2026 Guest: Thomas Briggs Chief Growth Officer at RedDrop Dx LinkedIn: https://www.linkedin.com/in/thomas-briggs-959865177/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Red Drop’s Bet on Pain-Free Blood Collection and the Next Wave of Diagnostics

  5. Jul 21

    Why Cancer Patients Still Die From Infections We Can't Diagnose - Karius

    In this episode of Diagnosing Dx, David Filby is joined by Alec Ford, Chief Executive Officer at Karius. Alec brings decades of leadership experience across therapeutics, vaccines, and genomics. In this conversation, we explore how Karius is bringing genomics into infectious disease and why the company has focused so sharply on immunocompromised patients. The scale of the unmet need is staggering. Alec explains that 52% of cancer deaths in the US are due to infection rather than the underlying malignancy, rising to more than 60% in hematologic malignancies. He also shares that there are around 4 million hospital admissions for infection among cancer patients in the US each year, yet the standard hospital workup can still fail to identify the cause in far too many cases. We also discuss the company’s growth, physician adoption, and why outpatient infectious disease testing could become a major next step. This is a practical conversation about infectious disease diagnostics, commercialization, and building in one of the most important unmet areas in healthcare. Key takeaways: 🔹 Why infectious disease remains one of the biggest threats to immunocompromised patients 🔹 How Karius is using microbial cell-free DNA to diagnose infection from a simple blood draw 🔹 Why focus and disciplined market selection have been central to Karius’ growth 🔹 How physician confidence and education shape adoption of new diagnostics 🔹 Why outpatient infectious disease testing could become a major next step for the field Chapters: 01:00 Introduction and Alec Ford’s background 04:20 Transition from therapeutics to genomics 08:34 The founding story of Karius and how the technology works 14:52 Why Karius focused on immunocompromised patients 19:41 Scaling the company and driving adoption 27:20 Reimbursement, capital strategy, and path to profitability 34:40 The outpatient opportunity and Karius’ next chapter 45:03 Alec’s view on the diagnostics industry and what needs to change Guest: Alec Ford Chief Executive Officer at Karius LinkedIn: https://www.linkedin.com/in/alec-ford-b578003/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ Learn more about Karius here: https://kariusdx.com/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Why Cancer Patients Still Die From Infections We Can't Diagnose - Karius

  6. Jul 15

    Can AI Rescue Cancer Drugs That Clinical Trials Say Have Failed?

    In this episode of Diagnosing Dx, David Filby is joined by Alexander Bagaev, Chief Product Officer at BostonGene. Alexander has spent more than a decade helping build BostonGene from an early-stage team into a global precision medicine company. In this conversation, we explore why oncology is moving beyond single biomarkers and how BostonGene has expanded from diagnostics into AI-powered treatment selection and clinical trial support. We also discuss the challenge of bringing more comprehensive diagnostics into routine use, the role of multimodal data in better decision-making, and how BostonGene is working with pharma to design smarter trials from the outset. This is a practical conversation about precision oncology, multimodal diagnostics, AI in drug development, and turning complex biology into clinically useful decisions. Key takeaways: 🔹 Why single-gene and narrow-panel testing often misses the full picture in oncology 🔹 How BostonGene is combining genomics, transcriptomics, and immune profiling to improve treatment selection 🔹 Why reimbursement still lags behind the scientific need for integrated diagnostics 🔹 How multimodal AI and foundation models could reshape drug development and clinical trial design 🔹 What precision medicine companies need to understand about flexibility, regulation, and real-world adoption Chapters: 00:00 Introduction to Alexander Bagaev 03:25 Journey from physics to immunology 05:07 The evolution of BostonGene 07:55 Precision medicine and patient-centric treatment selection 10:28 Challenges in drug development and clinical trials 13:02 Growth and milestones of BostonGene 15:19 Navigating diagnostics and the role of AI 20:48 Future opportunities and advice for early-stage companies Guest: Alexander Bagaev Chief Product Officer at BostonGene LinkedIn: https://www.linkedin.com/in/alexander-bagaev-5548166b/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Can AI Rescue Cancer Drugs That Clinical Trials Say Have Failed?

  7. Jul 7

    What If We Could Test Depression Drugs Before Patients Take Them? Dr Talia Cohen Solal - NeuroKaire

    In this episode of Diagnosing Dx, David Filby is joined by Talia Cohen Solal, CEO at NeuroKaire. Talia is a neuroscientist by training who spent more than a decade in academia, including time at Oxford, UCL, and Columbia, before moving into the startup world to get closer to real patient impact. In this conversation, we explore why precision medicine has transformed fields like oncology but still has so far to go in psychiatry, and how NeuroKaire is trying to change that. We discuss the limits of current antidepressant prescribing and how NeuroKaire is using patient-derived neurons to predict which treatments are most likely to work for each individual. This is a practical conversation about precision psychiatry, commercialization, clinical evidence, and what it takes to bring better mental health diagnostics into real patient care. Key takeaways: 🔹 Why psychiatry still lacks the precision medicine approach seen in other fields 🔹 How NeuroKaire is using patient-derived neurons to guide antidepressant treatment 🔹 Why clinical trials and guideline change are essential for real adoption 🔹 How the company is balancing commercial growth with platform expansion and pharma partnerships 🔹 What the future could look like for diagnostics in depression, anxiety, ADHD, and beyond Guest: Talia Cohen Solal CEO at NeuroKaire LinkedIn: https://www.linkedin.com/in/talia-cohen-solal-5b49a78/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ Chapters: 00:00 Introduction to Talia Cohen Solal and her background 08:23 Transitioning from academia to startups 09:52 The vision behind NeuroKaire and precision psychiatry 12:38 Clinical trials and validation of NeuroKaire’s technology 14:37 Commercialization, distribution, and reimbursement 16:46 Education and awareness in the medical community 19:44 Future growth, market potential, and new indications 26:47 Outlook on diagnostics and the future of neurodiagnostics 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    What If We Could Test Depression Drugs Before Patients Take Them? Dr Talia Cohen Solal - NeuroKaire

  8. Jun 30

    Why AI Multiomics Will Replace Ultrasound in Liver Cancer Screening with Bharat Tewarie

    In this episode of Diagnosing Dx, David Filby is joined by Bharat Tewarie, MD, MBA, CEO at Helio Genomics.   Bharat has led Helio Genomics since July 2025, bringing decades of global healthcare leadership across pharma, biotech, diagnostics, and digital health. In this conversation, we explore why liver cancer surveillance still relies too heavily on outdated imaging, why so many high-risk patients fall through the cracks, and how Helio Genomics is trying to change that with HelioLiver, its blood-based test designed to improve early detection.   We discuss the limitations of ultrasound in liver cancer screening, the promise of AI-powered multiomics, and why early detection only matters if patients can actually access it. Bharat also shares how his clinical and commercial background shapes Helio’s strategy, from workflow design and physician adoption to partnerships, awareness, and the infrastructure needed to move from scientific validation to real clinical impact.   This is a practical conversation about liver cancer, access, commercialization, and what it takes to turn better diagnostics into better outcomes.   Key takeaways:   🔹 Why liver cancer surveillance still leaves too many high-risk patients undetected 🔹 How AI-powered multiomics and HelioLiver could improve early liver cancer detection 🔹 Why access and workflow matter just as much as scientific performance 🔹 How partnerships can accelerate commercialization and patient reach 🔹 What Helio Genomics is building beyond HelioLiver as it expands its platform   Guest: Bharat Tewarie, MD, MBA CEO at Helio Genomics LinkedIn: https://www.linkedin.com/in/bharattewarie/   Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ Chapters: 00:00 Introduction to Bharat Tewarie and Helio Genomics 01:42 Bharat’s journey from medicine to business 06:25 The evolution of diagnostics, omics, and AI 10:36 Helio Genomics’ mission and differentiators 12:03 Unmet needs in liver cancer surveillance 14:01 Awareness, access, and clinical workflow challenges 19:10 The role of partnerships in commercialization 26:27 Growth strategy and the future of diagnostics   🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Why AI Multiomics Will Replace Ultrasound in Liver Cancer Screening with Bharat Tewarie
See All (96)

About

How do we transform cutting-edge scientific discoveries into life-saving diagnostics? On Diagnosing Dx, we explore the scientific innovation driving diagnostics forward, unpack industry challenges, and spotlight success stories. Join us as we speak with leading researchers and innovators at the forefront of Dx. Learn to: 🔹 Navigate industry challenges 🔹 Understand emerging science 🔹 Strategise for growth 🔹 Gain future-focused insight Essential listening for everyone involved in bringing new sciences to life in the Dx and Omics industry, Subscribe now!

Information

  • Creator
    Elevra Consulting
  • Years Active
    2025 - 2026
  • Episodes
    96
  • Rating
    Clean
  • Copyright
    © 2026 Elevra Consulting
  • Show Website
    Diagnosing Dx

You Might Also Like